Regeneron’s linvoseltamab shows promise in multiple myeloma trial By Investing.com – Canada Boosts
© Reuters. NEW YORK – Regeneron (NASDAQ:) Prescribed drugs has introduced encouraging outcomes from its part 1/2 LINKER-M1 trial for the remedy of relapsed or refractory a number of myeloma (R/R MM) with linvoseltamab, an experimental remedy. The trial reported a strong goal response fee (ORR) of 71% and a whole response fee of 46%…